Introduction
Microtubules play a central role in coordinating various cellular functions, including cell shape, motility, signal transduction and intracellular organelle transport during interphase, and the formation of mitotic spindles and the cytokinesis bridge during cell division. Such functions of microtubules are orchestrated by their interaction with molecular motors and their associated proteins. Anticancer drugs that target microtubule dynamics have been effective in cancer therapy. However, the role of microtubule-associated molecules in cancer cell proliferation is not clear.
NudC is a protein that associates with the microtubule motor dynein/dynactin complex that regulates microtubule dynamics . NUDC is a highly conserved protein, with homologues found from fungi to humans (Moreau et al., 2001) . In the fungus Aspergillus nidulans, nudC encodes a nuclear movement protein that is required for nuclear distribution along the developing germ tube and is essential for colony growth and viability (Osmani et al., 1990; Chiu et al., 1997) . In amphibians, de novo NudC synthesis is found during oogenesis, blastulation and gastrulation (Moreau et al., 2001) , a time when cells of different lineages have high proliferative as well as migratory capacity. In the mouse brain, NudC is highly expressed in the neuronal progenitor cells that are undergoing rounds of proliferation followed by migration out of the ventricular zone to establish the distinct layers of the developing cortex Aumais et al., 2001) .
We previously identified NudC as an early response gene induced in mitogen-stimulated T cells (Axtell et al., 1995) . Several studies show that elevated NudC levels correlate with the proliferative status of various cell types, tissues and tumors. NudC mRNA levels increase during mid-G1 and NudC protein levels double during G2/M phase of the cell cycle (Axtell et al., 1995) . NudC expression is elevated in mammalian cells with a high growth rate (Gocke et al., 2000a, b) , in clinical bone marrow isolates from patients with acute lymphoblastic or acute myelogenous leukemia (Miller et al., 1999) , and in prostate tumors derived from the TRAMP mouse (Aumais et al., 2000) . These observations suggest that NudC is involved in the proliferative process in normal as well as tumor tissues.
Since elevated NudC levels correlate with the proliferative status of various cell types, possibly through its involvement in microtubule function, we investigated a role of NudC in tumorigenesis of prostate cancer cells. We found that overexpression of NudC inhibited tumorigenesis of prostate cancer cells in both a soft agar colony assay and a subcutaneous xenograft mouse tumor model. The NudC-mediated inhibition of tumorigenesis in vivo is correlated with an inhibition of prostate cancer cell proliferation in vitro. Further, overexpression of NudC resulted in an increase in G2/ M DNA content in prostate cancer cells. Morphological analysis showed that a majority of NudC-overexpressing prostate cancer cells have increased in size and contained a single enlarged nucleus. Also abundant are binucleated and multinucleated cells. These observations suggest that overexpression of NudC blocks cell division through inhibition of karyokinesis (nuclear division) and/or cytokinesis (cytoplasmic division) of prostate cancer cells. Thus, although increased levels in NudC may be required for cell proliferation, overexpression of NudC results in inhibition of cell division. Thus, a proper level of NudC is critical for cell cycle progression. Our studies raise the interesting possibility that overexpression of NudC, a microtubule motorassociated protein, exerts a novel mechanism in tumor suppression by blocking mitosis and cytokinesis.
Results

Overexpression of NudC in LNCaP cells inhibits anchorage-independent growth
To investigate the role of NudC in tumorigenicity of prostate cancer cells, we generated recombinant adenovirus Ad-NudC to infect prostate cancer cells. AdLuciferase (Ad-Luc) was used as a control. LNCaP cells, which were derived from the lymph node metastasis of a prostate cancer patient (Horoszewicz et al., 1983) , were used initially. Western blot analysis of NudC expression following Ad-Luc or Ad-NudC infection with MOIs of 1, 2.5 and 5 showed that there was a dose-dependent increase of NudC expression in LNCaP cells infected with Ad-NudC ( Figure 1a , lanes 2-4). At this level of film exposure, endogenous NudC expression in AdLuc-infected LNCaP cells was not detectable (Figure 1a , lane 1). Equal proteins were loaded as shown by Western blotting with anti-b-actin antibodies.
The effect of NudC on the tumorigenic potential of LNCaP cells was analysed by examining its effect on anchorage-independent growth of LNCaP cells in a soft agar colony assay. LNCaP cells were infected with either Ad-NudC or Ad-Luc at different MOIs and incubated for 2 weeks in soft agar. As shown in Figure 1b , there was a dose-dependent inhibition of LNCaP cell growth in soft agar by NudC; inhibition was observed at an MOI of 1 and only few colonies were detected at an MOI of 5. In contrast, control LNCaP cells infected with Ad-Luc at an MOI of 5 showed robust colony growth. The number of colonies that grew from AdNudC-infected LNCaP cells was only B16% of those that grew from Ad-Luc-infected control cells. This observation suggests that increased expression of NudC inhibits anchorage-independent growth of LNCaP cells.
Ad-NudC gene transfer inhibits prostate tumor growth in vivo
Since increased NudC expression inhibited anchorageindependent growth of LNCaP cells, we further investigated whether NudC overexpression has an effect on prostate tumor growth in vivo. To address this, we employed DU145 and PC-3 cells, which were derived from brain (Stone et al., 1978) and bone metastasis (Kaighn et al., 1979) of prostate cancer patients, respectively, because they are highly tumorigenic when injected into nu/nu mice in a xenograft mouse model (Lin et al., 1999; Estrera et al., 2001) .
DU145 and PC-3 cells were infected with either control Ad-Luc or Ad-NudC at an MOI of 10 for 2 days. The infected cells were injected subcutaneously into the flanks of nu/nu mice. Animals injected with prostate cancer cells infected with control Ad-Luc Cells infected with control Ad-Luc continued to proliferate over 96 h, reaching three to four times the original cell number (Figures 3b, d ). However, cells infected with Ad-NudC failed to proliferate beyond 48 h postinfection, where the cell numbers remained unchanged from 48 to 96 h in both DU145 ( Figure 3b ) and PC-3 cells (Figure 3d) . At 96 h, the Ad-NudC-infected DU145 cells formed cell aggregates after trypsinization, and thus were not counted (Figure 3b, asterisk) . Similar results were obtained in two independent experiments (data not shown). These results show that overexpression of NudC inhibits prostate cancer cell proliferation in vitro.
NudC overexpression leads to an increase in G2/M DNA content
Cell cycle analysis was performed on Ad-Luc vs AdNudC-infected PC-3 cells to investigate the mechanism underlying the growth inhibition of PC-3 cells by NudC overexpression. Flow-cytometric analysis of Ad-NudCinfected PC-3 cells showed a twofold increase in cells with a G2/M DNA content at 24 h Ad-NudC infection, ) were infected and the cell numbers were counted as above. Two independent cell proliferation experiments were performed on DU145 and PC-3 cells, with essentially identical results (data not shown). Error bars are included, but may be too tight to see compared with that of the Ad-Luc-infected control cells (Figures 4e vs a) . By 48 h, the G2/M DNA content of Ad-NudC-infected cells was about threefold higher relative to the Ad-Luc-infected control (Figures 4f vs  b) . At 96 h postinfection, close to 60% of cells in AdNudC-infected prostate cancer cells exhibited G2/M DNA content, while less than 20% of cells in Ad-Lucinfected control cells showed G2/M DNA content (Figures 4h vs d) . These results suggest that overexpression of NudC inhibits prostate cancer cell proliferation by causing cells to accumulate with a G2/M DNA content.
NudC overexpression leads to aberrant mitosis progression
The large increase in cells containing G2/M DNA content prompted us to examine the morphology of AdNudC-infected cells by immunofluorescence microscopy. Cells were immunostained with anti-NudC antibodies ) (red), anti-b tubulin antibodies (green), and counterstained with DAPI (blue) to detect NudC expression, determine the general morphology of the cells and visualize the cell nuclei. An increased level of NudC immunostaining was observed in Ad-NudC-infected DU145 (Figures 5a-c) and PC-3 (Figures 5e-g ) cells at 24 h through 72 h postinfection, consistent with an increase in NudC protein levels detected by Western blot analysis following Ad-NudC infection (Figures 3a, c) . Nuclear staining with DAPI revealed several striking features of AdNudC-infected cells. First, there was a progressive increase in nuclear size over time (Figures 5a-c, e-g ). Using a MetaMorph software program (Talcott and Moore, 2000) to measure nuclear size, we found that B 45% of Ad-NudC-infected DU145 and PC-3 cells contained a single enlarged nucleus by 72 h (Figures  5d, h) . Second, there was a significant increase in binucleated (B6%, Figure 5b , arrows) and multinucleated (B10%, Figure 5f , asterisk) cells in AdNudC-infected DU145 and PC-3 cells compared with Ad-Luc-infected control cells (data not shown). Further, the multinucleated and the single enlarged nucleated Ad-NudC-infected cells also had increased cell cytoplasm, as indicated by b-tubulin staining. Taken together, these results suggest that overexpression of NudC leads to nuclear enlargement and multinucleation of prostate cancer cells, suggesting that overexpression of NudC resulted in a failure to complete cell division, possibly through the inhibition of both mitosis and cytokinesis.
Discussion
NudC was isolated as an early growth-related gene in response to mitogenic stimulation by prolactin, suggesting that its expression is associated with cell proliferation (Axtell et al., 1995; Morris et al., 1997) . Consistent with this initial observation, NudC expression is increased in various cell types undergoing mitosis (Gocke et al., 2000a, b) or stimulated to proliferate (Aumais et al., 2000; Gocke et al., 2000a, b) , with high levels observed in leukemic cells and tumors (Aumais et al., 2000) . We thus investigated whether increasing NudC expression will have an effect on the tumorigenic potential of prostate cancer cells. We found that overexpression of NudC significantly inhibited the tumorigenicity of prostate cancer cells, as demonstrated by inhibition of anchorage-independent growth of LNCaP cells (Figure 1) and inhibition of the growth of DU145 and PC-3 cells in vivo in a mouse xenograft tumor model (Figure 2) . We further showed that the mechanism of NudC-mediated antitumor effect involves an inhibition of mitosis progression. This is the first report on the role of NudC in modulating tumor growth, and suggests that a microtubule motorassociated protein can have a significant effect on prostate tumor growth.
The observation that NudC levels normally double as cells undergo mitosis (Morris and Yu-Lee, 1998) but , which are likely due to a failure in karyokinesis (nuclear division) and/or cytokinesis (cytoplasmic division) (Nigg, 2002) , both of which are late events in cell division. We previously observed that overexpression of NudC in HeLa cells primarily caused a cytokinesis failure Zhou et al., 2003) . In this study, we found that overexpression of NudC in prostate cancer cells mainly caused a G2/M block ( Figure 4) and/or karyokinesis failure in addition to cytokinesis failure ( Figure 5) . Thus, overexpression of NudC elicits distinct cell division abnormalities in a cell-type-dependent manner. These effects of NudC on cell division are distinct from those of other cell cycle regulator proteins such as p21, p27 and the retinoblastoma protein Rb, which regulate early steps of cell cycle progression (Angus et al., 2002; Gartel and Tyner, 2002; Bloom and Pagana, 2003) .
Based on these observations, we propose a working model for the effect of NudC on cell division (Figure 6 ). In this model, we suggest that NudC may regulate cell cycle progression at multiple points, including G2, karyokinesis and cytokinesis. During normal mitosis, an increase in NudC levels may be required for progression through the cell cycle. This is consistent with a doubling of NudC levels in highly proliferative cells Gocke et al., 2000a, b) . However, a large excess of NudC can lead to aberrant cell cycle progression, resulting in an increase in large cells with a single enlarged nucleus and binucleated and multinucleated cells ( Figure 5 ). Binucleated cells can result from cytokinesis failure or aborted cell division. Subsequent mitoses in the binucleated cells generate multinucleated cells that often form large cells with single enlarged nuclei (Nigg, 2002) . The accumulation of large cells with a single enlarged nucleus can also result from a G2/M block, where cells have duplicated their chromosomes but fail to enter mitosis, or from karyokinesis failure in which cells have entered mitosis but fail to complete nuclear division.
NudC may affect cell cycle progression through its association with the microtubule motor dynein/dynactin complex. The dynein/dynactin motor complex drives many aspects of mitosis, including centrosome separation during prophase (Quintyne et al., 1999; Nigg, 2001) , nuclear envelope breakdown (Beaudouin et al., 2002; Salina et al., 2002) , kinetochore capture by microtubules, chromosome attachment to spindle microtubules (Coquelle et al., 2002; Tai et al., 2002) , chromosome movement towards the spindle poles (Banks and Heald, 2001 ) and proper spindle orientation during mitosis (Karki and Holzbaur, 1999; Dujardin and Vallee, 2002) . The dynein/dynactin complex may also play a role during cytokinesis, as they are localized to the cleavage furrow/midzone region and at the midbody during the last stage of cytoplasmic division (Karki et al., 1998; Straight and Field, 2000) . We previously showed that NudC co-immunoprecipitates with dynein/dynactin and colocalizes with dynein/dynactin at many microtubule-based structures , raising the possibility that NudC participates in dynein motor-driven, microtubule-related functions during mitosis and cytokinesis. Consistent with this possibility, genetic evidence in Aspergillus nidulans suggests that NudC is linked functionally to the dynein/dynactin motor complex (Morris, 2000; Han et al., 2001) . In mammalian cells, NudC is found in a dynein/dynactin complex that includes other factors such as Lis-1 (Coquelle et al., 2002; Tai et al., 2002) , NudE and NudEL (Baas, 1999; Niethammer et al., 2000) , which are thought to regulate microtubule dynamics and organization (Faulkner et al., 2000; Smith et al., 2000; Zhang et al., 2002; Yan et al., 2003) . Overexpression of some of the components of the dynein/ dynactin complex and its associated proteins altered microtubule organization and centrosome integrity (Echeverri et al., 1996; Quintyne et al., 1999; Faulkner et al., 2000; Smith et al., 2000; Coquelle et al., 2002; Quintyne and Schroer, 2002; Ligon et al., 2003) . Similarly, overexpression of NudC is likely to alter the stability or organization of microtubule structures in dividing cells. How NudC affects microtubule structure and function during mitosis and cytokinesis requires further investigation.
Blocking of microtubule function during mitosis progression is one of the strategies widely used in cancer chemotherapy. Drugs that interfere with microtubules such as taxol and taxotere are commonly used and have been shown to be effective in cancer treatment (Rowinsky and Donehower, 1995; Wood et al., 2001; Chen and Horwitz, 2002; Peterson and Mitchison, 2002) . Although NudC is not a typical tumor-suppressor protein, as is Rb or p53, its interaction with the dynein/dynactin motor and microtubule structures indicates that deregulation of NudC expression can interfere with mitosis as well as cytokinesis, leading to inhibition of tumor growth. These findings raise the interesting possibility that NudC, a dynein and microtubule-associated protein, has tumor-suppressive activity, and may be a new target for cancer therapy. 
Materials and methods
Recombinant adenovirus constructions
cDNA encoding full-length rat NudC was inserted into the adenovirus (Ad) shuttle vector pXCMV at the HindIII/NotI sites to generate pXCMV-NudC. The recombinant adenovirus Ad-NudC was generated by cotransfecting pXCMV-NudC and pJM17, which contains the adenoviral genome with the E1 gene deleted, into 293 cells, as previously described (Estrera et al., 2001) . Recombinant virus containing the luciferase gene (Ad-Luc) was used as a control.
Western blot analysis
Ad-NudC-or Ad-Luc-infected cells were trypsinized. Aliquots of the cell suspension were boiled in SDS sample buffer, and Western blot analysis was performed with a polyclonal antibody generated against maltose-binding protein (MBP)-NudC fusion protein (anti-NudC antibodies) (Morris and YuLee, 1998) . Expression of b-actin using anti-b-actin antibodies (Santa Cruz Biotechnology, CA, USA) was used as a control.
Measurement of anchorage-independent growth
The soft agar colony assay described by Giancotti and Ruoslahti (1990) was used to measure the anchorageindependent growth of LNCaP cells (Horoszewicz et al., 1983) . LNCaP cells were infected with Ad-Luc or Ad-NudC at the MOI as indicated for 48 h. The cells were plated onto sixwell plates and incubated for 2 weeks in soft agar. Colony number was used as an indication of anchorage-independent growth.
Tumorigenicity study DU145 (Stone et al., 1978) or PC-3 (Kaighn et al., 1979) cells were infected with Ad-NudC or Ad-Luc with an MOI of 10 for 48 h. Cells were harvested and resuspended in MEM. Cells (2 Â 10 6 cells in a total volume of 100 ml) were injected subcutaneously into the flanks of nu/nu mice. In all, 12 tumors were monitored weekly for each treatment group. The sizes of the tumors were calculated according to Rockwell et al. (1972) .
Cell growth and DNA content analysis
For in vitro growth rate analysis, Ad-NudC-and Ad-Lucinfected cells were trypsinized and counted with a hemacytometer 24, 48 and 96 h after plating. For DNA content analysis, cells were fixed with 70% ethanol, followed by staining with 50 mg/ml of propidium iodide. After treating the fixed cells with RNAse A (100 mg/ml) for 30 min at 371C, the DNA contents of the cells were analysed by fluorescenceactivated cell sorter (FACS) on a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA) equipped with an argon-ion laser (15 mW, 488 nm). The red fluorescence from propidium iodide was captured in the FL3 channel.
Immunofluorescence staining DU145 or PC-3 cells were infected with Ad-NudC or Ad-Luc at MOIs of 10. After incubation at 371C for various times as indicated, the cells were fixed for 20 min at room temperature in PEM (80 mM K-PIPES, 5 mM EGTA, 2 mM MgCl 2 ) with 4% (w/v) polyethylene glycol-6000 (PEG), 4% (v/v) EM-grade formaldehyde (Electron Microscopy Sciences, Ft. Washington, PA, USA) and 0.5% Triton X-100. Cells were incubated with rabbit anti-NudC antibodies and mouse anti-b-tubulin antibodies (tub2.1, Sigma), followed by incubation with Texas-red goat-anti-rabbit IgG (Molecular Probes) and FITC goat-antimouse IgG (Southern Biotechnologies). Slides were mounted in Vectashield mounting medium (Vector Labs, Burlingame, CA, USA) containing 4 0 ,6-diamidino-2-phenylindole (DAPI). A MetaMorph version 4.01 software program (Universal Imaging Corporation) was used to measure the nuclear size as described (Talcott and Moore, 2000) .
